Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Bayram Farisoğulları"'
Publikováno v:
RMD Open, Vol 8, Iss 2 (2022)
The current COVID-19 pandemic raises several clinical challenges. Cases of COVID-19-associated arthritis have been reported, and inconsistently described as either COVID-19 viral arthritis or COVID-19 reactive arthritis. We aimed to review all the re
Externí odkaz:
https://doaj.org/article/6c358d826ef34fc6904c3343b1eb4886
Autor:
Bayram, Farisoğulları, Gözde Kübra, Yardımcı, Alper, Sarı, Emre, Bilgin, Ertuğrul Çağrı, Bölek, Emine, Duran, Levent, Kılıç, Ali, Akdoğan, Ömer, Karadağ, Şule, Apraş Bilgen, Ali İhsan, Ertenli, Sedat, Kiraz, Umut, Kalyoncu
Publikováno v:
Clinical and Experimental Rheumatology. 40:112-119
To compare enteropathic spondylitis (ES) with psoriatic spondylitis (PS) and ankylosing spondylitis (AS), in patients on biological disease-modifying anti-rheumatic drug (bDMARD) treatment.Patients who were enrolled in the HUR-BIO registry were inclu
Autor:
Bayram Farisoğulları, Gözde Kübra Yardımcı, Alper Sarı, Berkan Armağan, Emre Bilgin, Ertuğrul Çağrı Bölek, Emine Duran, Gizem Ayan, Zehra Özsoy, Güllü Sandal Uzun, Levent Kılıç, Ali Akdoğan, Ömer Karadağ, Şule Apraş Bilgen, Ali İhsan Ertenli, Sedat Kiraz, Umut Kalyoncu
Publikováno v:
Ulusal Romatoloji Dergisi. 13:107-115
Autor:
İhsan Ertenli, Umut Kalyoncu, Sedat Kiraz, Şule Apraş Bilgen, Levent Kılıç, Hakan Oral, Bayram Farisoğulları, Berkan Armağan
Publikováno v:
Acta Medica. :1-8
Objective: Intravenous immunoglobulin is an alternative therapeutic agent that can be used off-label in many autoimmune rheumatological diseases. The aim of this study is to evaluate the autoimmune rheumatological diseases characteristics in which in
Autor:
Berkan Armağan, Levent Kılıç, Bayram Farisoğulları, Gözde Kübra Yardımcı, Emre Bilgin, Ertuğrul Çağrı Bölek, Ömer Karadağ, Şule Apraş Bilgen, Sedat Kiraz, İhsan Ertenli, Umut Kalyoncu
Publikováno v:
Rheumatology international.
The drug retention rate has been an important indicator for evaluating the treatment tolerance. Unfortunately, our knowledge of the secukinumab retention rate in radiographic axial spondyloarthritis (r-AxSpA) is limited. The objective of this study w
Autor:
Gözde Kübra Yardımcı, Beste Ekin Sandalcı Yıldırım, Bayram Farisoğulları, Levent Kilic, Omer Karadag
Publikováno v:
Annals of the rheumatic diseases.
Publikováno v:
Seminars in Arthritis and Rheumatism. 56:152078
Achievement of remission is a desirable outcome and the identification of predictors of remission may aid in the clinical management of axial spondyloarthritis (axSpA). Our aim was to summarise predictors of remission in people with axSpA.In this sys
Autor:
Alper, Sarı, Ömer, Önder, Berkan, Armağan, Ertuğrul Çağrı, Bölek, Bayram, Farisoğulları, Emre, Bilgin, Gözde Kübra, Yardımcı, Macit, Arıyürek, Ali, Akdoğan
Publikováno v:
Turkish journal of medical sciences. 52(1)
To explore the frequency and clinical associations of radiologic pleuroparenchymal fibroelastosis (PPFE) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).In this single-center retrospective study, high resolution com
Autor:
Pedro M Machado, Emma Dures, Gary J Macfarlane, Coziana Ciurtin, George Young, Fiona Cramp, Eduardo Santos, Bayram Farisogullari, Katie Fishpool, Emmanuel Oghenetejiri Erhieyovwe, Jen Pearson
Publikováno v:
BMJ Open, Vol 14, Iss 5 (2024)
Introduction Fatigue is an important and distressing symptom for many people living with chronic musculoskeletal (MSK) conditions. Many non-pharmacological interventions have been investigated in recent years and some have been demonstrated to be eff
Externí odkaz:
https://doaj.org/article/220e880fe9c5433c848689d162223c01
Autor:
Emre, Bilgin, Bayram, Farisoğulları, Berkan, Armağan, Alper, Sarı, Gözde K, Yardımcı, Ertuğrul Ç, Bölek, Levent, Kılıç, Ali, Akdoğan, Şule A, Bilgen, Ömer, Karadağ, A İhsan, Ertenli, Sedat, Kiraz, Umut, Kalyoncu
Publikováno v:
Clinical and experimental rheumatology. 38(4)
To assess the real-life retention rate of certolizumab and factors related to retention of certolizumab.We analysed all patients who received at least 1 dose of certolizumab and were registered in the HURBIO database. Patients with at least 1 control